Study Of Diltiazem In Patients With Chronic Myocardial Ischemia Under Absence Of Coronary Artery Revascularization

Objective To explore the efficacy and safety of diltiazem in patients with chronic myocardial ischemia under absence of coronary artery revascularization.Methods Ninety patients with coronary heart disease and without coronary artery revascularization were divided into control group(45 cases)and diltiazem group(45 cases)according to whether diltiazem was used or not.Patients in both groups had received conventional secondary prevention therapies of coronary artery disease,and patients in the diltiazem group were treated with diltiazem sustained-release capsules.Follow-up was performed 6 months after treatment and to record the occurrence of major adverse cardiovascular events.6-minute walk distances(6MWD)and the Seattle Angina Questionnaire standard scores were compared at baseline and at the end of follow-up between two groups.Results At the end of follow-up,Seattle Angina Questionnaire standard scores and 6MWD of two groups were all higher than those at baseline(P<0.05).At the end of follow-up,Seattle Angina Questionnaire standard scores and 6MWD in diltiazem group were higher than those in control group(P<0.05).At the end of follow-up,the resting heart rate of the two groups were all lower than those at the baseline(P<0.05),but there were no significant differences of left ventricular ejection fraction,ALT and serum creatinine of two groups compared with those at baseline(P>0.05).At the end of follow-up,resting heart rate in the diltiazem group was lower than that in the control group(P<0.05),but there were no significant differences of left ventricular ejection fraction,ALT and serum creatinine between two groups(P>0.05).There was no significant difference in the incidence of major adverse cardiovascular events between control group and the diltiazem group during the follow-up(17.8% vs 8.9%,P>0.05).Conclusion Diltiazem is effective and safe in improving angina pectoris and exercise tolerance in patients with chronic myocardial ischemia under absence of coronary artery revascularization.